Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2019 10:16 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
May 16, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports 2019 First Quarter Financial Results

OCALA Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types...
May 13, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

OCALA, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
May 08, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

OCALA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with...
May 06, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
April 30, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
April 25, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019

OCALA, Fla., April 25, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,...
April 22, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer

OCALA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
April 02, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab

OCALA, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell...
April 01, 2019 17:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports 2018 Year-end Financial Results

OCALA, Fla., April 01, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business...